1. Home
  2. ORMP vs SKYE Comparison

ORMP vs SKYE Comparison

Compare ORMP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORMP
  • SKYE
  • Stock Information
  • Founded
  • ORMP 2002
  • SKYE 2012
  • Country
  • ORMP United States
  • SKYE United States
  • Employees
  • ORMP N/A
  • SKYE N/A
  • Industry
  • ORMP Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORMP Health Care
  • SKYE Health Care
  • Exchange
  • ORMP Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • ORMP 90.7M
  • SKYE 80.7M
  • IPO Year
  • ORMP N/A
  • SKYE N/A
  • Fundamental
  • Price
  • ORMP $2.40
  • SKYE $3.16
  • Analyst Decision
  • ORMP Hold
  • SKYE Buy
  • Analyst Count
  • ORMP 1
  • SKYE 6
  • Target Price
  • ORMP N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • ORMP 493.3K
  • SKYE 214.0K
  • Earning Date
  • ORMP 03-05-2025
  • SKYE 02-25-2025
  • Dividend Yield
  • ORMP N/A
  • SKYE N/A
  • EPS Growth
  • ORMP N/A
  • SKYE N/A
  • EPS
  • ORMP 0.11
  • SKYE N/A
  • Revenue
  • ORMP N/A
  • SKYE N/A
  • Revenue This Year
  • ORMP N/A
  • SKYE N/A
  • Revenue Next Year
  • ORMP N/A
  • SKYE N/A
  • P/E Ratio
  • ORMP $21.93
  • SKYE N/A
  • Revenue Growth
  • ORMP N/A
  • SKYE N/A
  • 52 Week Low
  • ORMP $2.00
  • SKYE $2.31
  • 52 Week High
  • ORMP $3.67
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • ORMP 55.14
  • SKYE 52.61
  • Support Level
  • ORMP $2.16
  • SKYE $2.60
  • Resistance Level
  • ORMP $3.09
  • SKYE $3.54
  • Average True Range (ATR)
  • ORMP 0.15
  • SKYE 0.48
  • MACD
  • ORMP 0.03
  • SKYE 0.03
  • Stochastic Oscillator
  • ORMP 28.87
  • SKYE 34.73

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: